In the last trading session, 1.8 million shares of the Travere Therapeutics Inc (NASDAQ:TVTX) were traded, and its beta was 0.75. Most recently the company’s share price was $21.10, and it changed around -$0.65 or -2.99% from the last close, which brings the market valuation of the company to $1.84B. TVTX currently trades at a discount to its 52-week high of $22.25, offering almost -5.45% off that amount. The share price’s 52-week low was $5.12, which indicates that the current value has risen by an impressive 75.73% since then. We note from Travere Therapeutics Inc’s average daily trading volume that its 10-day average is 1.41 million shares, with the 3-month average coming to 1.33 million.
Travere Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.25. If we narrow it down even further, the data shows that 0 out of 16 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 2 recommended TVTX as a Hold, whereas 11 deemed it a Buy, and 0 rated it as Underweight. Travere Therapeutics Inc is expected to report earnings per share of -0.37 for the current quarter.
Travere Therapeutics Inc (NASDAQ:TVTX) trade information
Instantly TVTX has showed a red trend with a performance of -2.99% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 22.25 on recent trading dayincreased the stock’s daily price by 5.17%. The company’s shares are currently up 21.13% year-to-date, but still up 4.35% over the last five days. On the other hand, Travere Therapeutics Inc (NASDAQ:TVTX) is 11.05% up in the 30-day period. We can see from the shorts that 9.58 million shares have been sold at a short interest cover period of 7.3 day(s).
The consensus price target as assigned by Wall Street analysts is $21.5, which translates to bulls needing to increase their stock price by 1.86% from its current value. Analyst projections state that TVTX is forecast to be at a low of $12 and a high of $33.
Travere Therapeutics Inc (TVTX) estimates and forecasts
The year-over-year growth rate is expected to be 59.14%, up from the previous year.
Consensus estimates provided by 15 financial analysts predict the company will bring in an average of 72.63M in revenue for the current quarter. 7 analysts expect Travere Therapeutics Inc to make 71.47M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 45.06M and 41.37M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 61.18%. Forecasts for the next quarter put sales growth at 72.75%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -12.34%.
TVTX Dividends
Travere Therapeutics Inc’s next quarterly earnings report is expected to be released in March.
ARMISTICE CAPITAL, LLC, with 9.6774% or 7.5 million shares worth $61.65 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
